Literature DB >> 8088602

Uterine papillary serous carcinoma: patterns of metastatic spread.

B A Goff1, D Kato, R A Schmidt, M Ek, J A Ferry, H G Muntz, J M Cain, H K Tamimi, D C Figge, B E Greer.   

Abstract

Uterine papillary serous carcinoma (UPSC) is a distinct histologic type of endometrial cancer which is associated with a high relapse rate and poor prognosis. Between 1983 and 1993, 50 patients with UPSC of the endometrium were surgically staged. Thirty-three patients had pure UPSC and 17 had UPSC admixed with other histologies. Extrauterine disease was found in 36 women (72%). Lymph node metastases were present in 36% of women without myometrial invasion, 50% with inner one-half invasion, and 40% with outer one-half invasion. Similarly, the presence of intraperitoneal disease or positive washings did not correlate with increasing myometrial invasion. Grade and histology (mixed vs pure) were also not predictive of extrauterine disease. Patients with lymphatic/vascular space invasion (LVSI) were more likely to have extrauterine disease (85%); however, even without LVSI the incidence of extrauterine disease was 58% (P = 0.05). Unlike endometrioid adenocarcinomas, grade and depth of myometrial invasion were not significant predictors for extrauterine disease. This study reinforces the need for complete surgical staging in all patients with UPSC regardless of depth of invasion.

Entities:  

Mesh:

Year:  1994        PMID: 8088602     DOI: 10.1006/gyno.1994.1208

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  64 in total

1.  Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.

Authors:  P Mhawech-Fauceglia; R F Herrmann; J Kesterson; I Izevbaye; S Lele; K Odunsi
Journal:  Eur J Surg Oncol       Date:  2010-12       Impact factor: 4.424

2.  Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma.

Authors:  Ivy Wilkinson-Ryan; Antonina I Frolova; Jingxia Liu; L Stewart Massad; Premal H Thaker; Matthew A Powell; David G Mutch; Andrea R Hagemann
Journal:  Int J Gynecol Cancer       Date:  2015-01       Impact factor: 3.437

3.  A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?

Authors:  June Y Hou; Thomas C McAndrew; Gary L Goldberg; Kathleen Whitney; Shohreh Shahabi
Journal:  Reprod Sci       Date:  2013-09-10       Impact factor: 3.060

4.  Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

Authors:  Stefania Bellone; Jonathan Black; Diana P English; Carlton L Schwab; Salvatore Lopez; Emiliano Cocco; Elena Bonazzoli; Federica Predolini; Francesca Ferrari; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Am J Obstet Gynecol       Date:  2015-08-10       Impact factor: 8.661

5.  Robotic surgery compared with laparotomy for high-grade endometrial cancer.

Authors:  Alok Pant; Julian Schink; John Lurain
Journal:  J Robot Surg       Date:  2014-01-12

Review 6.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

Review 7.  Endometrial cancer: the management of high-risk disease.

Authors:  Gunnar Kristensen; Claes Tropé
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

8.  Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.

Authors:  Dana M Roque; Stefania Bellone; Diana P English; Natalia Buza; Emiliano Cocco; Sara Gasparrini; Ileana Bortolomai; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

9.  Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

Authors:  Karim El-Sahwi; Stefania Bellone; Emiliano Cocco; Francesca Casagrande; Marta Bellone; Maysa Abu-Khalaf; Natalia Buza; Fattaneh A Tavassoli; Pei Hui; Dominik Rüttinger; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

Review 10.  HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.

Authors:  Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.